elubrixin
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00504439)
Timeline
Indications
Mechanism of action
- Interleukin-8 receptor BANTAGONIST
CXCR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(F)c1Cl- Mol. weight
- 463.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2178579 ↗
Also known as
- elubrixin
- elubrixin
- elubrixin
- sb656933
- sb656933
- sb656933
- sb 656933
- sb-656933
- sb-656933
- sb-656933
- sb-656933
- sb-656933-aaf
- sb-656933-aaf
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00903201 | Phase 2 | Sep 1, 2009 | GlaxoSmithKline |
| NCT00748410 | Phase 2 | Jan 1, 2009 | GlaxoSmithKline |
| NCT00615576 | Phase 1 | Mar 1, 2008 | GlaxoSmithKline |
| NCT00605761 | Phase 1 | Feb 1, 2008 | GlaxoSmithKline |
| NCT00551811 | Phase 1 | Oct 1, 2007 | GlaxoSmithKline |
| NCT00504439 | Phase 1 | Jun 1, 2007 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2007 |
1 organizations
Page 1 / 1